We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.95B
1-Year Est. Return
773.9%
This Fund
S&P 500
This Quarter
Est. Return
+19.76%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.95B
AUM Growth
-$39.6M
(-2%)
Cap. Flow
-$245M
Cap. Flow
% of AUM
-12.56%
Top 10 Holdings %
Top 10 Hldgs %
59.19%
Holding
59
New
12
Increased
4
Reduced
29
Closed
9
Avg Time Held Equity + Options
6
quarters
Top 10 Avg Time Held Equity + Options
2.5
quarters
Top 20 Avg Time Held Equity + Options
3.9
quarters
Avg Time Held Equity only
6
quarters
Top 10 Avg Time Held Equity only
3.3
quarters
Top 20 Avg Time Held Equity only
4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$128M |
| 2 |
Climb Bio
CLYM
|
+$21.8M |
| 3 |
Faeth Therapeutics
FTH
|
+$16.7M |
| 4 |
Spyre Therapeutics
SYRE
|
+$16.4M |
| 5 |
Adlai Nortye Group ADS
ANL
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$77.7M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.7M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$25.9M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$23.4M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.09% |
| 2 | Financials | 0.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Axsome Therapeutics
AXSM
$8.7B
| – | – |
-50,000
| Closed | -$8.45M | – |
|
|
CNTA
52
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,050,000
| Closed | -$41.7M | – |
|
53
Context Therapeutics
CNTX
$28M
| – | – |
-529,550
| Closed | -$1.39M | – |
|
54
Monte Rosa Therapeutics
GLUE
$897M
| – | – |
-400,000
| Closed | -$6.58M | – |
|
|
55
CALL
Olema Pharmaceuticals
OLMA
$644M
| – | – |
-500,000
| Closed | -$7.46M | – |
|
56
Rallybio
RLYB
$89.2M
| – | – |
-400,000
| Closed | -$3.59M | – |
|
57
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-300,000
| Closed | -$15.8M | – |
|
58
Zura Bio
ZURA
$383M
| – | – |
-1,450,000
| Closed | -$8.63M | – |
|
59
Maze Therapeutics
MAZE
$1.54B
| – | – |
-750,000
| Closed | -$22.4M | – |
|
Similar funds
AHC
FFS
GIP
SLF
BFPW
MSA
MAM
GF
Cormorant Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Cormorant Asset Management held 59 positions worth $1.95B, down 2% from $1.99B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Cormorant Asset Management withdrew a net $245M in Q2 2026, closing 9 positions and reducing 29 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $41.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Parabilis Medicines Inc worth $126M.
- Cormorant Asset Management's largest Q2 2026 buy was Parabilis Medicines Inc: 4,615,612 shares worth $126M.
- Cormorant Asset Management added most to Faeth Therapeutics in Q2 2026, an estimated $16.7M increase.
- Cormorant Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $77.7M.
- Cormorant Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.7M.
- Cormorant Asset Management's ten largest holdings make up 59% of its $1.95B portfolio in Q2 2026.
- Cormorant Asset Management opened 12 new positions and closed 9 in Q2 2026.
- Cormorant Asset Management's portfolio value fell 2% quarter-over-quarter to $1.95B.
Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.